Leveraging Real-World Evidence in NMIBC Therapy Evaluations

Video content above is prompted by the following:

Real-world evidence (RWE) currently plays a limited role in health plan decision-making for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) treatments, primarily due to the absence of standardized evaluation frameworks and the legal requirement for payers to defend coverage decisions with established clinical evidence. Health plans view RWE as supplementary “nice-to-have” information rather than primary decision-making data, particularly for newly launched therapies where limited real-world usage data exists. The reliance on controlled clinical trial data remains predominant, as these studies provide the regulatory foundation necessary for formulary coverage justification.

The landscape for RWE utilization is rapidly evolving through initiatives led by the Academy of Managed Care Pharmacy (AMCP), which is developing comprehensive frameworks with specific protocols for incorporating real-world data into coverage decisions. This framework addresses different drug life cycle phases, from preapproval through postlaunch periods, establishing data requirements for each stage. At product launch, the framework emphasizes pragmatic clinical trials, external control arms and economic modeling, focusing on primary end points that demonstrate value versus standard of care and address unmet medical needs.

For established therapies like pembrolizumab with extensive postmarket experience, abundant real-world data provide high confidence levels for formulary evaluation, contrasting sharply with newly approved treatments lacking comprehensive real-world utilization patterns. The framework considers specific outcomes relevant to NMIBC, including complete response rates, cystectomy-free survival, adverse events and comparative analyses between treatment options. As RWE standards mature, health plans anticipate greater integration of real-world outcomes data into formulary management, potentially revolutionizing how coverage decisions are made for complex oncology treatments like those used in BCG-unresponsive bladder cancer management.